FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207788380> ?p ?o ?g. }

• W3207788380 endingPage "112" @default.
• W3207788380 startingPage "105" @default.
• W3207788380 abstract "PurposeInitial findings in patients with cancer suggest a lower seroconversion to SARS-CoV-2 vaccination possibly related to myelo-immunosuppressive therapies. We conducted a prospective study to assess factors predicting poor seroconversion and adverse events following immunisation (AEFI) to the BNT162b2 vaccine in patients on active treatment.Patients and methodsCancer patients, candidates to two doses of BNT162b2 SARS-CoV-2 vaccination, were enrolled. Patients on active surveillance served as controls. The primary endpoint was poor seroconversion (anti S1/S2 IgG < 25 AU/mL) after 21 days from the second dose.ResultsBetween March and July 2021, 320 subjects were recruited, and 291 were assessable. The lack of seroconversion at 21 days from the second dose was 1.6% (95% CI, 0.4–8.7) on active surveillance, 13.9% (8.2–21.6) on chemotherapy, 11.4% (5.1–21.3) on hormone therapy, 21.7% (7.5–43.7) on targeted therapy and 4.8% (0.12–23.8) on immune-checkpoint-inhibitors (ICI). Compared to controls, the risk of no IgG response was greater for chemotherapy (p = 0.033), targeted therapy (0.005) and hormonotherapy (p = 0.051). Lymphocyte count < 1 × 109/L (p = 0.04) and older age (p = 0.03) also significantly predicted poor seroconversion. Overall, 43 patients (14.8%) complained of AEFI, mostly of mild grade. Risk of AEFI was greater in females (p = 0.001) and younger patients (p = 0.009).ConclusionChemotherapy, targeted therapy, hormone therapy, lymphocyte count < 1 × 109/L, and increasing age predict poor seroconversion after two doses of BNT162b2 in up to 20% of patients, indicating the need for a third dose and long-term serological testing in non-responders. AEFI occur much more frequently in women and younger subjects who may benefit from preventive medications.ClinicalTrials.gov IdentifierNCT04932863." @default.
• W3207788380 created "2021-10-25" @default.
• W3207788380 creator A5001801088 @default.
• W3207788380 creator A5003304101 @default.
• W3207788380 creator A5009720057 @default.
• W3207788380 creator A5009809962 @default.
• W3207788380 creator A5010571821 @default.
• W3207788380 creator A5015077519 @default.
• W3207788380 creator A5019347720 @default.
• W3207788380 creator A5019429500 @default.
• W3207788380 creator A5032502657 @default.
• W3207788380 creator A5036397891 @default.
• W3207788380 creator A5041195716 @default.
• W3207788380 creator A5041670560 @default.
• W3207788380 creator A5045197511 @default.
• W3207788380 creator A5049232758 @default.
• W3207788380 creator A5049851605 @default.
• W3207788380 creator A5061015160 @default.
• W3207788380 creator A5062291346 @default.
• W3207788380 creator A5063987935 @default.
• W3207788380 creator A5065520270 @default.
• W3207788380 creator A5073693721 @default.
• W3207788380 creator A5075772633 @default.
• W3207788380 creator A5082173251 @default.
• W3207788380 date "2021-12-01" @default.
• W3207788380 modified "2023-10-17" @default.
• W3207788380 title "Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment" @default.
• W3207788380 cites W1577251139 @default.
• W3207788380 cites W1906010766 @default.
• W3207788380 cites W2070779815 @default.
• W3207788380 cites W2518536270 @default.
• W3207788380 cites W2555965680 @default.
• W3207788380 cites W3023020711 @default.
• W3207788380 cites W3030573714 @default.
• W3207788380 cites W3036543467 @default.
• W3207788380 cites W3046287740 @default.
• W3207788380 cites W3080162924 @default.
• W3207788380 cites W3082920121 @default.
• W3207788380 cites W3087639085 @default.
• W3207788380 cites W3093367571 @default.
• W3207788380 cites W3111255098 @default.
• W3207788380 cites W3117702394 @default.
• W3207788380 cites W3124144456 @default.
• W3207788380 cites W3130161221 @default.
• W3207788380 cites W3131998187 @default.
• W3207788380 cites W3134724758 @default.
• W3207788380 cites W3138703198 @default.
• W3207788380 cites W3145657260 @default.
• W3207788380 cites W3157453497 @default.
• W3207788380 cites W3158078097 @default.
• W3207788380 cites W3159505699 @default.
• W3207788380 cites W3165390631 @default.
• W3207788380 cites W3172958999 @default.
• W3207788380 cites W3174054271 @default.
• W3207788380 cites W3176552995 @default.
• W3207788380 cites W3176961880 @default.
• W3207788380 cites W3213468071 @default.
• W3207788380 doi "https://doi.org/10.1016/j.ejca.2021.09.030" @default.
• W3207788380 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8502731" @default.
• W3207788380 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34742157" @default.
• W3207788380 hasPublicationYear "2021" @default.
• W3207788380 type Work @default.
• W3207788380 sameAs 3207788380 @default.
• W3207788380 citedByCount "29" @default.
• W3207788380 countsByYear W32077883802022 @default.
• W3207788380 countsByYear W32077883802023 @default.
• W3207788380 crossrefType "journal-article" @default.
• W3207788380 hasAuthorship W3207788380A5001801088 @default.
• W3207788380 hasAuthorship W3207788380A5003304101 @default.
• W3207788380 hasAuthorship W3207788380A5009720057 @default.
• W3207788380 hasAuthorship W3207788380A5009809962 @default.
• W3207788380 hasAuthorship W3207788380A5010571821 @default.
• W3207788380 hasAuthorship W3207788380A5015077519 @default.
• W3207788380 hasAuthorship W3207788380A5019347720 @default.
• W3207788380 hasAuthorship W3207788380A5019429500 @default.
• W3207788380 hasAuthorship W3207788380A5032502657 @default.
• W3207788380 hasAuthorship W3207788380A5036397891 @default.
• W3207788380 hasAuthorship W3207788380A5041195716 @default.
• W3207788380 hasAuthorship W3207788380A5041670560 @default.
• W3207788380 hasAuthorship W3207788380A5045197511 @default.
• W3207788380 hasAuthorship W3207788380A5049232758 @default.
• W3207788380 hasAuthorship W3207788380A5049851605 @default.
• W3207788380 hasAuthorship W3207788380A5061015160 @default.
• W3207788380 hasAuthorship W3207788380A5062291346 @default.
• W3207788380 hasAuthorship W3207788380A5063987935 @default.
• W3207788380 hasAuthorship W3207788380A5065520270 @default.
• W3207788380 hasAuthorship W3207788380A5073693721 @default.
• W3207788380 hasAuthorship W3207788380A5075772633 @default.
• W3207788380 hasAuthorship W3207788380A5082173251 @default.
• W3207788380 hasBestOaLocation W32077883801 @default.
• W3207788380 hasConcept C121608353 @default.
• W3207788380 hasConcept C126322002 @default.
• W3207788380 hasConcept C159654299 @default.
• W3207788380 hasConcept C188816634 @default.
• W3207788380 hasConcept C197934379 @default.
• W3207788380 hasConcept C203014093 @default.
• W3207788380 hasConcept C22070199 @default.
• W3207788380 hasConcept C2776694085 @default.

• next